Methods for reducing toxicity of a chemotherapeutic drug
AssigneeMayo Foundation for Medical Education and Research
InventorsSvetomir N. Markovic, Wendy K. Nevala
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, by reducing chemotherapy-related toxicity to a level that allows the chemotherapeutic drug to be used in humans.
Claims20
A method for providing an acceptable therapeutic index of a chemotherapeutic drug targeting aberrant mammalian cells, which method comprises:
- a) combining a therapeutically effective amount of said drug with a biocompatible protein carrier, wherein the drug has an unacceptable therapeutic index when administered alone;
- b) forming a complex with said carrier and an effective amount of an antibody which has specificity to an antigen on said aberrant cells, wherein said antibodies populate the surface of said complex and retain binding specificity;
- and
- c) administering said complex to a patient, wherein said administration enhances delivery of said drug to said cells and reduces one or more side effects of said drug, thereby increasing the therapeutic index of said drug to provide an acceptable therapeutic index.
A method for providing an acceptable therapeutic index of a chemotherapeutic drug targeting tumor cells, which method comprises:
- a) combining a therapeutically effective amount of said drug with an albumin carrier, wherein the drug has an unacceptable therapeutic index when administered alone;
- b) forming a complex with said carrier and an effective amount of an antibody which has specificity to an antigen on said tumor cells, wherein said antibodies populate the surface of said complex and retain binding specificity;
- and
- c) administering said complex to a patient wherein said administration enhances delivery of said drug to said tumor cells and reduces one or more side effects of said drug, thereby increasing the therapeutic index of said drug.
A method of reducing chemotherapy drug-related toxicity in a patient having cancer, which method comprises treating said patient with a complex comprising a therapeutically effective amount of a chemotherapy drug with an albumin carrier, and an effective amount of antibody which has specificity to an antigen on said cancer, wherein said antibodies populate the surface of said complex and retain binding specificity, wherein the chemotherapy drug has an unacceptable therapeutic index when administered alone, such that said patient has reduced risk of chemotherapy drug-related toxicity.
A method for providing an acceptable therapeutic index of a chemotherapeutic drug targeting aberrant mammalian cells, which method comprises:
- a) combining a therapeutically effective amount of said drug with a biocompatible protein carrier, wherein the drug has an unacceptable therapeutic index when administered alone;
- b) forming a complex with said carrier and an effective amount of binding agent having specificity to said aberrant cells, wherein said binding agent populates the surface of said complex and retain specificity and further wherein said binding agent has a protein carrier-binding portion;
- and
- c) administering said complex to a patient, wherein said administration enhances delivery of said drug to said cells and reduces one or more side effects of said drug, thereby increasing the therapeutic index of said drug.
Dependencies are inferred from the claim text.